IP Library › Granted Patent US 10,413,743
Granted Patent B2
US 10,413,743 · App. 15/728,238 · Granted Sep 17, 2019

Pacing device with autonomous anti-tachycardia pacing

Inventor: Jacob M. Ludwig (Isanti, MN)
Assignee: Cardiac Pacemakers, Inc.
A61N1/3962A61B5/042A61B5/0464A61B5/4836A61N1/3621A61N1/3622A61N1/3931A61N1/0504A61N1/0563
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,413,743
App. No.
15/728,238
Granted
Sep 17, 2019
Kind
B2
Abstract

In an example, an apparatus is described that includes an implantable housing, a heart signal sensing circuit configured to sense intrinsic electrical heart signals, a ventricular tachyarrhythmia (VT) detector circuit, operatively coupled to the heart signal sensing circuit, the detector circuit operable to detect a VT based on the sensed heart signals, a processor configured to control delivery of an anti-tachyarrhythmia pacing (ATP) therapy based on the detected VT, and an energy delivery circuit configured to deliver the ATP therapy in response to the detected VT, wherein the apparatus does not include a shock circuit capable of delivering a therapeutically-effective cardioverting or defibrillating shock.

Claims (40)

1. A system comprising:

a first device including:

a first implantable housing;

a plurality of subcutaneous electrodes configured to sense a plurality of electrical signals;

a first processor configured to control delivery of a defibrillation shock therapy based on the sensed electrical signals;

a first energy delivery circuit configured to deliver the shock therapy; and

a second device including:

a second implantable housing;

a heart signal sensing circuit configured to sense intrinsic electrical heart signals;

a shock detector circuit, operatively coupled to the heart signal sensing circuit, the shock detector circuit operable to detect the delivery of shock therapy;

a second processor configured to control delivery of a post-shock pacing therapy based on the detected delivery of shock therapy; and

a second energy delivery circuit configured to deliver the post-shock pacing therapy,

wherein the second processor is configured to disable delivery of post-shock pacing therapy based on an indication of the absence from the system or unavailability of the first energy delivery circuit.

2. The system of claim 1 , wherein the second processor is configured to control delivery of the post-shock pacing therapy without a communicated request from the first device.

3. The system of claim 1 , wherein the second device is configured to receive at least one post-shock pacing therapy parameter, and wherein the second processor is configured to control the delivery of the post-shock pacing therapy based on the at least one received post-shock pacing therapy parameter.

4. The system of claim 3 , wherein the second device is configured to receive at least one post-shock pacing therapy parameter, and wherein the second processor is configured to enable or disable the delivery of the post-shock pacing therapy based on the at least one received post-shock pacing therapy parameter.

5. The system of claim 1 , wherein the second device comprises:

a ventricular tachyarrhythmia (VT) detector circuit, operatively coupled to the heart signal sensing circuit, the VT detector circuit operable to detect a VT based on the sensed heart signals,

wherein the second processor is configured to control delivery of an anti-tachyarrhythmia pacing (ATP) therapy based on the detected VT, and

wherein the second energy delivery circuit is configured to deliver the ATP therapy.

6. The implantable device of claim 5 , wherein the second processor is further configured to stop delivery of ATP when a shock therapy is detected by the shock detector circuit.

7. The system of claim 5 , wherein the second processor is configured to deliver ATP therapy when the VT detector circuit detects a VT based on the sensed heart signals and stop delivering ATP therapy when a shock is detected, wherein risk of acceleration initiated by the ATP therapy is mitigated by delivery of defibrillation therapy by the implantable defibrillator device.

8. A system comprising:

a first implantable medical device (IMD), the first IMD comprising:

a plurality of subcutaneous electrodes configured to sense a plurality of electrical signals;

a first processor configured to control delivery of a first cardiac electrical therapy based on the sensed electrical signals; and

a first energy delivery circuit configured to deliver shock therapy; and

a second IMD comprising:

a heart signal sensing circuit configured to sense intrinsic electrical heart signals;

a ventricular tachyarrhythmia (VT) detector circuit, operatively coupled to the heart signal sensing circuit, the VT detector circuit operable to detect a VT based on the sensed heart signals;

a second processor configured to control delivery of an anti-tachyarrhythmia pacing (ATP) therapy based on the detected VT; and

a second energy delivery circuit configured to deliver the ATP therapy

wherein the second processor is configured to disable delivery of the ATP based on an indication of the absence from the system or unavailability of the first energy delivery circuit.

9. The system of claim 8 , wherein the second processor is configured to control delivery of the ATP therapy without a communicated request from the first device.

10. The system of claim 8 , wherein the second device is configured to receive at least one ATP therapy parameter, and wherein the second processor is configured to enable or disable the delivery of the ATP therapy based on the at least one received ATP therapy parameter.

11. The system of claim 8 , wherein the second device comprises:

a shock detection module to detect delivery of the shock therapy.

12. The system of claim 11 , wherein the second processor is configured to inhibit or stop delivery of the ATP therapy when the shock detection module detects delivery of the shock therapy.

13. The system of claim 11 , wherein the second device is configured to receive at least one post-shock pacing therapy parameter, and wherein the second processor is configured to control the delivery of the post-shock pacing therapy based on the at least one received post-shock pacing therapy parameter.

14. The system of claim 11 , wherein the second device is configured to receive at least one post-shock pacing therapy parameter, and wherein the second processor is configured to enable or disable the delivery of the post-shock pacing therapy based on the at least one received post-shock pacing therapy parameter.

Continuity (3)
Division 14620862 · Feb 12, 2015
Provisional Application 61979634 · Apr 15, 2014
Related Publication 20180028829A1 · Feb 1, 2018